Pediatric Nephrology

, Volume 23, Issue 12, pp 2215–2220 | Cite as

Bisphosphonates in children with hypercalciuria and reduced bone mineral density

Original Article


Previous studies have demonstrated reduced bone mineral density (BMD) and biochemical changes of excessive bone resorption in some patients with idiopathic hypercalciuria (IH). Consequently, bisphosphonates have been successfully employed in research animals and adults with IH and reduced BMD. We evaluated the effect of treatment with bisphosphonates in seven patients ages 10–16 years with persistent IH and reduced BMD. In five children, preceding traditional therapy failed. All children received oral alendronate and one also IV Zoledronic acid for 6–18 (median 9.0, mean 10.7) months. With treatment, BMD Z scores in the lumbar spine improved from −2.0 ± 0.3 to −0.8 ± 0.8 (p = 0.002) and in the femoral neck from −1.8 ± 0.4 to −0.7 ± 0.9 (p = 0.01); urine N-telopeptides/creatinine decreased from 372 ± 289 to 72 ± 39 nmol/mmol (p = 0.05) and calcium/creatinine from 0.29 ± 0.12 to 0.13 ± 0.06 mg/mg (p = 0.009). Height Z scores, normal at baseline in all, remained unaffected, and no new stones or fractures were documented throughout the treatment period. Serum creatinine, electrolytes, calcium, phosphorus and parathyroid hormone remained normal as well. In summary, in children with IH and decreased BMD, treatment with bisphosphonates normalized urine calcium excretion, eliminated urinary symptoms, and significantly improved reduced BMD. These short-term beneficial effects indicate the need for larger prospective studies on the potential of bisphosphonates to serve as a new tool in treating children with IH and reduced BMD.


Bisphosphonates Bone mineral density Bone resorption Calciuria Osteopenia 



This work was supported in part by The Sam and Helen Kaplan Research Fund in Pediatric Nephrology and The Eric McClure Research Fund in Pediatric Bone and Mineral Diseases. We thank Regina Johnson, Connie Haney, RN, and Michal Alon, RN, for their valuable assistance.


  1. 1.
    Weisinger JR (1999) Bone loss in hypercalciuria: cause or consequence? Am J Kidney Dis 33:46–48CrossRefGoogle Scholar
  2. 2.
    Srivastava T, Alon US (2007) Pathophysiology of hypercalciuria in children. Pediatr Nephrol 22:1569–1573CrossRefGoogle Scholar
  3. 3.
    Alon US (2008) Medical treatment of pediatric urolithiasis. Pediatr Nephrol doi: 10.1007/s00467-007-0740-7
  4. 4.
    Weisinger JR, Alonzo E, Bellorín-Font E, Blasini AM, Rodriguez MA, Paz-Martínez V, Martinis R (1996) Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria. Kidney Int 49:244–250PubMedCrossRefGoogle Scholar
  5. 5.
    Ghazali A, Fuentès V, Desaint C, Bataille P, Westeel A, Brazier M, Prin L, Fournier A (1997) Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria. J Clin Endocrinol Metab 82:32–38PubMedCrossRefGoogle Scholar
  6. 6.
    Giannini S, Nobile M, Sartori L, Calò L, Tasca A, Dalle Carbonare L, Ciuffreda M, D’Angelo A, Pagano F, Crepaldi G (1998) Bone density and skeletal metabolism are altered in idiopathic hypercalciuria. Clin Nephrol 50:94–100PubMedGoogle Scholar
  7. 7.
    Caudarella R, Vescini F, Buffa A, La Manna G, Stefoni S (2004) Osteoporosis and urolithiasis. Urol Int 72(Suppl 1):17–19PubMedCrossRefGoogle Scholar
  8. 8.
    Jaeger P, Lippuner K, Casez JP, Hess B, Ackerman D, Hug C (1994) Low bone mass in idiopathic renal stone formers: magnitude and significance. J Bone Miner Res 10:1525–1532Google Scholar
  9. 9.
    García-Nieto V, Ferrández C, Monge M, de Sequera M, Rodrigo MD (1997) Bone mineral density in pediatric patients with idiopathic hypercalciuria. Pediatr Nephrol 11:578–583PubMedCrossRefGoogle Scholar
  10. 10.
    Freundlich M, Alonzo E, Bellorin-Font E, Weisinger JR (2002) Reduced bone mass in children with idiopathic hypercalciuria and in their asymptomatic mothers. Nephrol Dial Transplant 17:1396–1401PubMedCrossRefGoogle Scholar
  11. 11.
    Penido MG, Lima EM, Marino VS, Tupinambá AL, França A, Souto MF (2002) Bone alterations in children with idiopathic hypercalciuria at the time of diagnosis. Pediatr Nephrol 18:133–139PubMedGoogle Scholar
  12. 12.
    Schwaderer AL, Cronin R, Bates CM, Mahan JD (2007) Increased incidence of osteoporosis in children with hypercalciuria and/or nephrolithiasis. Pediatric Academic Societies E-PAS2007:615874.1 (abstract)Google Scholar
  13. 13.
    Skalova S, Palicka V, Kutilek S (2005) Bone mineral density and urinary N-acetyl-beta-D-glucosaminidase activity in paediatric patients with idiopathic hypercalciuria. Nephrology 10:99–102PubMedCrossRefGoogle Scholar
  14. 14.
    Kessenich CR, Rosen CJ (1996) The pathophysiology of osteoporosis. In: Rosen CJ (ed) Osteoporosis, diagnostic and therapeutic principles. Humana Press, Totowa, pp 47–63Google Scholar
  15. 15.
    Bushinsky DA, Neumann KJ, Asplin J, Krieger NS (1999) Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int 55:234–243PubMedCrossRefGoogle Scholar
  16. 16.
    Heller HJ, Zerwekh JE, Gottschalk FA, Pak CY (2007) Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. Kidney Int 71:808–815PubMedCrossRefGoogle Scholar
  17. 17.
    Arrabal Martín M, Díaz de la Guardia FV, Jiménez Pacheco A, López León V, Arrabal Polo MA, Zuluaga Gómez A (2007) The treatment of renal lithiasis with bisphosphonates. Arch Esp Urol 60:745–754PubMedCrossRefGoogle Scholar
  18. 18.
    Freundlich M (2006) Bone mineral content and mineral metabolism during cyclosporine treatment of nephrotic Syndrome. J Pediatr 149:383–389PubMedCrossRefGoogle Scholar
  19. 19.
    Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141Google Scholar
  20. 20.
    Leonard MB, Propert KJ, Zemel BS, Stallings VA, Feldman HI (1999) Discrepancies in pediatric bone mineral density reference data: potential for misdiagnosis of osteopenia. J Pediatr 135:182–188PubMedCrossRefGoogle Scholar
  21. 21.
    Leib ES, Lewiecki EM, Binkley N, Hamdy RC (2004) Official positions of the International Society for Clinical Densitometry. J Clin Densitom 7:1–5PubMedCrossRefGoogle Scholar
  22. 22.
    Asplin JR, Donahue S, Kinder J, Coe FL (2006) Urine calcium excretion predicts bone loss in idiopathic hypercalciuria. Kidney Int 70:1463–1467PubMedCrossRefGoogle Scholar
  23. 23.
    Stapleton FB, Jones DP, Miller LA (1989) Evaluation of bone metabolism in children with hypercalciuria. Semin Nephrol 9:75–78PubMedGoogle Scholar
  24. 24.
    Weisinger JR (1996) New insights into the pathogenesis of idiopathic hypercalciuria: the role of bone. Kidney Int 49:1507–1518PubMedCrossRefGoogle Scholar
  25. 25.
    Adams JS, Song CF, Kantorovich V (1999) Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann Intern Med 130:658–660PubMedGoogle Scholar
  26. 26.
    LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE (2000) Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 133:516–526PubMedGoogle Scholar
  27. 27.
    Sellmeyer DE, Schloetter M, Sebastian A (2002) Potassium citrate prevents increased urine calcium excretion and bone resorption induced by a high sodium chloride diet. J Clin Endocrinol Metab 87:2008–2012PubMedCrossRefGoogle Scholar
  28. 28.
    Pak CY, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD (2003) Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. J Urol 169:465–469PubMedCrossRefGoogle Scholar
  29. 29.
    Reusz GS, Dobos M, Vasarhelyi B, Sallay P, Szabo A, Horvath C, Szabo A, Byrd DJ, Thole HH, Tulassay T (1998) Sodium transport and bone mineral density in hypercalciuria with thiazide treatment. Pediatr Nephrol 12:30–34PubMedCrossRefGoogle Scholar
  30. 30.
    Quan A, Adams R, Ekmark E, Baum M (2003) Bone mineral density in children with myelomeningocele: effect of hydrochlorothiazide. Pediatr Nephrol 18:929–933PubMedCrossRefGoogle Scholar
  31. 31.
    Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T (2005) Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 44:813–818CrossRefGoogle Scholar
  32. 32.
    Reusz GS, Dobos M, Tulassay T, Miltényi M (1993) Hydrochlorothiazide treatment of children with hypercalciuria: effects and side effects. Pediatr Nephrol 7:699–702PubMedCrossRefGoogle Scholar
  33. 33.
    Marini JC (2003) Do bisphosphonates make children’s bones better or brittle? N Engl J Med 349:423–426PubMedCrossRefGoogle Scholar
  34. 34.
    Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676–1679PubMedCrossRefGoogle Scholar
  35. 35.
    Cummings SR, Schwartz AV, Black DM (2007) Alendronate and atrial fibrillation. N Engl J Med 356:1895–1896PubMedCrossRefGoogle Scholar
  36. 36.
    Papapoulos SE, Cremers SC (2007) Prolonged bisphosphonate release after treatment in children. N Engl J Med 356:1075–1076PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2008

Authors and Affiliations

  1. 1.Pediatric NephrologyUniversity of MiamiMiamiUSA
  2. 2.Bone and Mineral Disorders Clinic, Section of Pediatric Nephrology, Children’s Mercy Hospital and ClinicsUniversity of Missouri–Kansas City, School of MedicineKansas CityUSA
  3. 3.Pediatric Nephrology, Childrens Mercy HospitalKansas CityUSA

Personalised recommendations